| Literature DB >> 32426546 |
Rosliza Yahaya1, Mohd Nizam Zahary2, Zahiruddin Othman3, Rusli Ismail1, Nik Ahmad Shaiffudin Nik Him1, Aniza Abd Aziz1, Rahima Dahlan4, Azizul Fadzli Jusoh1.
Abstract
INTRODUCTION: Schizophrenia is a chronic mental illness with clusters of symptoms, including cognitive impairment. This study aimed to explore the effect of Tualang Honey (TH) on cognitive domains, especially as it pertained to the verbal memory of schizophrenia patients.Entities:
Keywords: AVLT; Alternative medicine; Biological psychiatry; Clinical psychology; Clinical research; Cognitive enhancer; Honey; Neuroscience; Psychiatry; Schizophrenia
Year: 2020 PMID: 32426546 PMCID: PMC7226648 DOI: 10.1016/j.heliyon.2020.e03948
Source DB: PubMed Journal: Heliyon ISSN: 2405-8440
Inclusion and exclusion study criteria.
| Inclusion Criterias | Exclusion Criterias |
|---|---|
Schizophrenia patient according to the (DSM-5) | Cognitive disorder such as delirium and dementia |
BPRS score <30 | Substance intoxication or withdrawal |
Able to speak understand Malay language | Intellectual disabilities |
Neurocognitive impairment | |
Medical condition that affected with intervention substances such as diabetes mellitus or acromegaly. | |
Severe communication problems such as deafness and mute | |
Regular benzodiazepine or anticholinergic medications |
Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5), Brief Psychiatric Rating Scale (BPRS).
Figure 1(a): Total learning score and (b): Delayed recall scores of MVAVLT performance in control group (n = 40), and honey group (n = 40) at pre-intervention and intervention. The differences between pre-intervention and post-intervention scores for each group were analysed using RM ANCOVA. Covariates appearing in the model are evaluated at the following values: Age in years = 30.98, Education in years = 12.66, Overall duration of illness in months = 107.68. MVALVLT, Malay version of the Auditory Verbal Learning Test, RM ANCOVA, Repeated measure analysis of covariance.
Socio-demographic and clinical characteristics of subjects (n = 80).
| Characteristic | TH group (n = 40) | Control group (n = 40) | p-value | ||
|---|---|---|---|---|---|
| Mean (SD) | Frequency (%) | Mean (SD) | Frequency (%) | ||
| Age in years | 31.43 (8.68) | 30.53 (7.89) | 0.629 | ||
| Age at first treatment (years) | 22.05 (7.55) | 22.70 (6.82) | 0.688 | ||
| Sex | 0.370 | ||||
| Male | 21 (55.3) | 17 (44.7) | |||
| Female | 19 (45.2) | 23 (54.8) | |||
| Marital status | 0.533 | ||||
| Single | 12 (57.1) | 9 (42.9) | |||
| Married | 3 (60.0) | 2 (40.0) | |||
| Divorced/Separated | 2 (100.0) | 0 (0.0) | |||
| Employment | 0.937 | ||||
| Unemployed | 19 (46.3) | 22 (53.7) | |||
| Employed | 21 (55.3) | 17 (44.7) | |||
| Educational (years) | 12.70 (2.52) | 12.63 (2.20) | 0.888 | ||
| Duration of illness (months) | 112.65 (86.82) | 92 (66.30) | 0.235 | ||
| Duration of treatment (months) | 119.55 (86.88) | 95.80 (66.18) | 0.173 | ||
| Admission | 0.237 | ||||
| Never been admitted | 11 (40.7) | 16 (59.3) | |||
| At least admitted once | 29 (54.7) | 24 (45.3) | |||
| Antipsychotic | 0.260 | ||||
| Atypical | 22 (46.8) | 25 (53.2) | |||
| Typical | 15 (62.5) | 9 (37.5) | |||
| Both | 3 (33.3) | 6 (66.7) | |||
Median (IQR).
Chi-square test.
Independent t test.
Comparison of MVALT score Trials within each treatment group based on time (Time effect).
| Comparison | Control | Honey | ||
|---|---|---|---|---|
| MD (95% CI) | p- value | MD (95% CI) | p- value | |
| Total learning | ||||
| Pre-Post Total (A1 + A2 + A3 + A4 + A5) | 0.38 (1.00,1.75) | 0.584 | 2.40 (0.53, 4.27) | 0.013∗ |
| Delayed recall | ||||
| Pre- Post A7 | 0.25 (0.07,0.57) | 0.122 | 0.33 (0.05,0.70) | 0.085 |
Repeated measure ANCOVA within-group analysis was applied followed by pairwise comparison with confidence interval adjustment (Bonferroni correction), Binary covariate (age, education duration and illness duration) was controlled by using repeated measure ANCOVA.
MD = mean difference.
Comparison of MVALT score Trials among two treatment group based on time (Time treatment interaction).
| Trials | Time | Treatment Group | Mean Score | 95% CI | F- stat (df) | p-value |
|---|---|---|---|---|---|---|
| Total Learning scores | ||||||
| (A1 + A2 + A3 + A4 + A5) | Pre-treatment | Control | 24.50 | 21.42, 27.59 | 4.46 (1) | 0.038∗ |
| Honey | 26.10 | 23.01, 29.18 | ||||
| Post-treatment | Control | 24.69 | 21.14, 28.24 | |||
| Honey | 28.68 | 25.13, 32.23 | ||||
| Delayed Recall scores | ||||||
| A7 | Pre-treatment | Control | 4.37 | 3.47, 5.26 | 0.31 (1) | 0.582 |
| Honey | 4.98 | 4.09, 5.88 | ||||
| Post-treatment | Control | 4.58 | 3.68, 5.49 | |||
| Honey | 5.34 | 4.44, 6.25 | ||||
A6 scores do not contribute to outcome interpretation.
Mean difference of MVALT score trials among two (between-group).
| Trials | Comparison | Mean Score difference (95% CI) | F-stat (df) | P-value |
|---|---|---|---|---|
| Total learning | ||||
| A1+A2+A3+A4+A5 | Control- Honey | 2.79 (1.80,17.38) | 1.46 (1) | 0.230 |
| Delayed Recall | ||||
| A7 | Control- Honey | 0.69 (0.571,1.95) | 1.19 (1) | 0.280 |
A6 scores do not contribute to outcome interpretation.
Repeated measure ANCOVA between-group analysis was applied, followed by pairwise comparison.
Binary covariate (age, education duration and illness duration) was controlled by using repeated measure ANCOVA.
Level of significance was set at 0.05 (two-tailed).